Bello N, Meyers KJ, Workman J, Hartley L, McMahon M. Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis. Lupus. 2023 Mar;32(3):325-41. doi: 10.1177/09612033221147471
Stander S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M. Worst itch numerical rating scale for Prurigo Nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):573-81. doi: 10.1111/jdv.17870
Alsumali A, Chemaly RF, Graham J, Jiang Y, Merchant S, Miles L, Schelfhout J, Yang J, Tang Y. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. J Med Virol. 2021 Jun;93(6):3786-94. doi: 10.1002/jmv.26462
Campbell K, Niare S, Herman Kuiper J. A mathematical model of cartilage regeneration after chondrocyte and stem cell implantation – II: the effects of co-implantation. J Tissue Eng. 2019 Mar 15;10:1-14. doi: 10.1177/2041731419827792
Campbell K, Naire S, Herman Kuiper J. A mathematical model of cartilage regeneration after chondrocyte and stem cell implantation – I: the effects of growth factors. J Tissue Eng. 2019 Mar;10:1-16. doi: 10.1177/2041731419827791
Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478
Ferris ME, Harward DH, Bickford K, Layton JB, Ferris MT, Hogan SL, Gipson DS, McCoy LP, Hooper SR. A clinical tool to measure the components of health-care transition from pediatric care to adult care: the UNC TR(x)ANSITION scale. Ren Fail. 2012;34(6):744-53. doi: 10.3109/0886022X.2012.678171
So TY, Layton JB, Bozik K, Farrington E, Gipson PE, Gibson K, Primack W, Conley, 3rd W, Gipson DS, Ferris M. Cognitive pharmacy services at a pediatric nephrology and hypertension clinic. Ren Fail. 2011 Jan 10;33(1):19-25. doi: 10.3109/0886022X.2010.536291
McKennas SP, Whalley D, deProst Y, Staab D, Huels J, Paul CF, vanAssche D. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006 Mar 1;20(3):248-54.
Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18.
Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P. Measuring quality of life in lupus: development of the SLEQoL. Poster presented at the First EADV International Spring Symposium; February 2003. [abstract] J Eur Acad Dermatol Venereol. 2003 Mar; 17(Suppl 1):58.